Access the full text.
Sign up today, get DeepDyve free for 14 days.
Although prior studies provide evidence that investment in research and development (R&D) expenditure enhances a firm’s performance, very little evidence is available on the impact of a firm’s life cycle stages on the association between R&D expenditures and firm performance. We classify firms into three-life cycle stages, namely, growth, mature and stagnant, and choose four-life cycle classification variables which are dividends, sales growth, capital expenditure and firm age. Using 769-firm-year observations over a period of 11-years in Australia, we find that the abnormal returns to unexpected expensed R&D amounts are significantly negative. Further, our results suggest that market reaction to expensed R&D is more negatively pronounced during the stagnant phase of a firm’s life cycle, suggesting that the market perceives that firms have limited prospects to derive benefits arising out of expensed R&D expenditures. The results suggest that the relationship between performance and investment in R&D is not linear but is moderated by a firm’s life cycle which should be taken into account when making policy that is based on stock-based performance.
International Journal of Accounting, Auditing and Performance Evaluation – Inderscience Publishers
Published: Jan 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.